Skip to main content
Back
Watch Compare

Sonoma Pharmaceuticals, Inc.

Data quality: 100%
SNOA
Nasdaq Manufacturing Measuring & Analyzing Instruments
$2.41
▲ $0.12 (5.24%)
Mkt Cap: 4.17 M
Price
$2.41
Mkt Cap
4.17 M
Day Range
$2.23 — $2.60
52-Week Range
$1.92 — $6.92
Volume
82,136
Open $2.30
50D / 200D Avg
$2.73
11.73% below
50D / 200D Avg
$3.48
30.81% below

Quick Summary

Key Takeaways

Revenue declined -6.42% annually over 5 years
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -3.72 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 18.61%
Capital efficient — spends only 1.18% of revenue on capex

Growth

Revenue Growth (5Y)
-6.42%
Below sector avg (1.82%)
Revenue (1Y)12.19%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-93.36%
Below sector avg (-53.41%)
ROIC-23.01%
Net Margin-19.02%
Op. Margin-15.61%

Safety

Debt / Equity
0.00
Below sector avg (0.31)
Current Ratio2.88
Interest CoverageN/A

Valuation

PE (TTM)
-1.24
Above sector avg (-1.48)
P/B Ratio1.22
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.2 -1.5
P/B 1.2 1.6
ROE % -93.4 -53.4
Net Margin % -19.0 -41.5
Rev Growth 5Y % -6.4 1.8
D/E 0.0 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 12.19% Revenue Growth (3Y) 3.76%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -6.42% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 17.72 M Net Income (TTM) -3.37 M
ROE -93.36% ROA -24.53%
Gross Margin 38.16% Operating Margin -15.61%
Net Margin -19.02% Free Cash Flow (TTM) -3.72 M
ROIC -23.01% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 2.88
Interest Coverage N/A Asset Turnover 1.29
Working Capital 7.93 M Tangible Book Value 3.43 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.24 Forward P/E N/A
P/B Ratio 1.22 P/S Ratio 0.24
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -89.17%
Market Cap 4.17 M Enterprise Value 1.61 M
Per Share
EPS (Diluted TTM) -1.95 Revenue / Share 10.24
FCF / Share -2.15 OCF / Share -2.03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.18% FCF Conversion 110.36%
SBC-Adj. FCF -3.85 M Growth Momentum 18.61

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14.29 M 12.74 M 13.27 M 12.63 M 18.63 M
Net Income -3.46 M -4.84 M -5.15 M -5.09 M -3.95 M
EPS (Diluted) -2.79 -0.53 -1.52 — —
Gross Profit 5.47 M 4.75 M 4.48 M 3.99 M 6.56 M
Operating Income -3.71 M -4.70 M -4.57 M -5.89 M -3.45 M
EBITDA — — — — —
R&D Expenses 1.81 M 1.87 M 207,000.0 125,000.0 555,000.0
SG&A Expenses 7.36 M 7.58 M 8.84 M 9.76 M 9.45 M
D&A 138,000.0 176,000.0 125,000.0 186,000.0 227,000.0
Interest Expense — — 16,000.0 -10,000.0 12,000.0
Income Tax 550,000.0 -196,000.0 -33,000.0 -332,000.0 713,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 13.69 M 14.74 M 16.23 M 18.85 M 14.99 M
Total Liabilities 9.28 M 8.60 M 8.25 M 10.15 M 9.62 M
Shareholders' Equity 4.41 M 6.14 M 7.98 M 8.70 M 5.36 M
Total Debt 220,000.0 323,000.0 — 0.0 1.31 M
Cash & Equivalents 5.37 M 3.13 M 3.82 M 7.40 M 4.22 M
Current Assets 12.65 M 12.55 M 13.80 M 16.43 M 12.98 M
Current Liabilities 4.10 M 3.72 M 3.72 M 5.82 M 4.08 M